BioCentury | Feb 4, 2020
Product Development

Insmed planning Phase III for rare lung disorder therapy following mixed Phase II readout

Insmed rose $8.34 (41%) to $28.88 on Monday, gaining $745 million in market cap, after its chronic lung inflammation therapy met the primary endpoint in a Phase II study. But the data, which included an...
BC Innovations | Feb 9, 2018
Product R&D

R is for readout

While AstraZeneca plc gets credit for transparency in publishing its metrics on R&D productivity, the data cover well-established targets addressed by conventional modalities. The more telling test for its “5R framework” will be whether it...
BC Extra | Sep 5, 2017
Clinical News

Insmed jumps on Phase III success in rare lung infection

Insmed Inc. (NASDAQ:INSM) soared $14.70 (120%) to $26.99 on Tuesday and ended the day with about $1.7 billion in market cap after reporting that ALIS ( amikacin liposome inhalation suspension , Arikayce) met the primary endpoint of...
BC Week In Review | Oct 10, 2016
Company News

AstraZeneca, Insmed deal

AstraZeneca granted Insmed exclusive, worldwide rights to INS1007 (formerly AZD7986 ), a small molecule targeting dipeptidyl peptidase-1 ( DPP-1 ; CTSC ). AZ will receive $30 million up front and is eligible for up to $120...
BC Extra | Oct 5, 2016
Company News

Insmed in-licenses DPP-1 inhibitor from AstraZeneca

AstraZeneca plc (LSE:AZN; NYSE:AZN) granted pulmonary disease company Insmed Inc. (NASDAQ:INSM) exclusive, worldwide rights to AZD7986 , a small molecule inhibitor of dipeptidyl peptidase-1 ( DPP-1 ; CTSC ). The candidate, which Insmed renamed INS1007, has completed...
BC Week In Review | Sep 28, 2009
Company News

SARomics Biostructures, Unizyme deal

SARomics will use its structure-based drug design technologies to identify drug candidates targeting dipeptidyl peptidase-1 ( DPP-1 ) to treat inflammatory diseases for Unizyme. Unizyme will provide the small molecules for screening and will have exclusive, worldwide...
Items per page:
1 - 6 of 6